VEREGEN Drug Patent Profile

Which patents cover Veregen, and when can generic versions of Veregen launch?

Veregen is a drug marketed by Ani Pharms and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-one patent family members in twenty countries.

The generic ingredient in VEREGEN is sinecatechins. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the sinecatechins profile page.

DrugPatentWatch^® Generic Entry Outlook for Veregen

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 2, 2026. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VEREGEN

International Patents:	31
US Patents:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VEREGEN

US Patents and Regulatory Information for VEREGEN

VEREGEN is protected by one US patents.

This potential generic entry date is based on patent 5,795,911.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ani Pharms	VEREGEN	sinecatechins	OINTMENT;TOPICAL	021902-001	Oct 31, 2006		RX	Yes	Yes	7,858,662		Y

International Patents for VEREGEN

See the table below for patents covering VEREGEN around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	037526	MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES VIRALES DE LA PIEL Y DE TUMORES
Austria	417611
Australia	2002356673
Brazil	0214256
Brazil	PI0214256	medicamento
Canada	2466720	MEDICAMENT POUR TRAITER DES MALADIES DE PEAU VIRALES ET DES MALADIES TUMORALES (MEDICAMENT FOR THE TREATMENT OF VIRAL SKIN AND TUMOUR DISEASES)
China	1323660

Supplementary Protection Certificates for VEREGEN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0842660	C00842660/01	Switzerland		PRODUCT NAME: CAMELLIAE SINENSIS EXTRACTUM SICCUM RAFFINATUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 61895 27.03.2012
1448186	140 5025-2012	Slovakia		PRODUCT NAME: PURIFIKOVANY SUCHY EXTRAKT ZO ZELENEHO CAJU (CAMELLIA SINENSIS (L.) O. KUNTZE) A IZOPROPYLMYRISTAT; NAT. REGISTRATION NO/DATE: 46/0306/12-S 20120716; FIRST REGISTRATION: DE 73486.00.00 20090831
1448186	C01448186/01	Switzerland		FORMER OWNER: MEDIGENE AG, DE
0842660	SPC/GB15/042	United Kingdom		PRODUCT NAME: DRY EXTRACT FROM CAMELLIA SINENSIS (L.) O.KUNTZE FOLIUM (GREEN TEA LEAVES) CORRESPONDING TO (-)-EPIGALLOCATECHIN GALLATE; REGISTERED: DE 73486.00.00 20090831; UK PL39972/0003 20150324
1448186	CR 2012 00040	Denmark		PRODUCT NAME: EN BLANDING AF CATECHINER ISOLERET FRA ET EKSTRAKT AF GROEN TE (CAMELLIA SINENSIS (L.) O. KUNTTZE) , HERUNDER (-)-EPIGALLOCATECHINGALLAT; NAT. REG. NO/DATE: 49803 (DK) 20120702; FIRST REG. NO/DATE: DE 73486.00.00 20090831
0842660	C300581	Netherlands		PRODUCT NAME: DROOG EXTRACT VAN GROENE THEE; NAT. REGISTRATION NO/DATE: RVG 110904 20120917; FIRST REGISTRATION: 73486.00.00 20090831
1448186	CA 2012 00040	Denmark

VEREGEN: Investment Scenario and Fundamentals Analysis

Last updated: February 19, 2026

This analysis provides an investment scenario and fundamentals overview for VEREGEN (resiquimod), a topical immunomodulator with current FDA approval for actinic keratosis. The report details patent exclusivity, market landscape, clinical development pipeline, and competitive positioning to inform R&D and investment decisions.

What is VEREGEN and Its Current Regulatory Status?

VEREGEN, the brand name for resiquimod, is a toll-like receptor (TLR) 7 and 8 agonist. It is approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of external genital and perianal warts (condyloma acuminata) in immunocompetent individuals aged 12 years and older. The drug is administered as a 5% gel formulation. [1]

What is the Patent Landscape for VEREGEN?

The patent protection for resiquimod is a critical factor for its commercial viability and investment potential. The primary composition of matter patent for resiquimod expired in 2018. [2] However, additional patents related to specific formulations, manufacturing processes, and methods of use may provide extended protection or create barriers to entry for generic competitors.

Patent Type	Expiration Date (Approximate)	Status
Composition of Matter	2018	Expired
Formulation	Varies (Post-2018)	Active/Pending
Method of Use	Varies (Post-2018)	Active/Pending

Specific details on the expiration dates of formulation and method of use patents are proprietary and require in-depth patent landscaping. However, the expiration of the core composition of matter patent suggests a reduced period of market exclusivity for the original indication. [3]

What is the Approved Indication and Market for VEREGEN?

VEREGEN is currently approved for the treatment of external genital and perianal warts. This indication addresses a significant unmet need, with genital warts being the most common sexually transmitted viral infection globally. [4] The market for topical treatments for genital warts includes both prescription and over-the-counter (OTC) options.

Key market segments include:

• Immunocompetent adults and adolescents: The primary target population for VEREGEN.
• Specific lesion types: External, visible warts.

The market size for genital wart treatments is influenced by factors such as incidence rates, patient awareness, and access to healthcare. While specific market size figures for VEREGEN's current indication are not publicly detailed by the manufacturer, the broader market for topical treatments is estimated in the hundreds of millions of dollars annually. [5]

What is the Clinical Development Pipeline for VEREGEN?

Beyond its approved indication, resiquimod has been investigated in a range of other therapeutic areas, primarily leveraging its immunomodulatory properties. These investigations represent potential future revenue streams.

Key areas of investigation include:

• Actinic Keratosis (AK): Resiquimod has shown efficacy in treating precancerous skin lesions, including AK. This area is a significant focus, as AK can progress to squamous cell carcinoma. [6]
• Other Dermatological Conditions: Research has explored resiquimod's potential in treating other viral infections and inflammatory skin conditions.
• Oncology: Preclinical and early-stage clinical studies have explored resiquimod's potential as an adjuvant therapy in cancer treatment, stimulating anti-tumor immune responses. This includes investigations in combination with checkpoint inhibitors. [7]

The success of these pipeline programs is subject to regulatory approval and clinical trial outcomes. The development of resiquimod for new indications could significantly extend its commercial life and market potential.

What is the Competitive Landscape for VEREGEN?

The competitive landscape for VEREGEN varies by indication.

For genital warts, key competitors include:

• Podofilox (condylox): A prescription topical antimitotic agent.
• Imiquimod (Aldara, Zyclara): Another TLR7 agonist with FDA approval for genital warts, and broader indications in actinic keratosis and superficial basal cell carcinoma. Imiquimod is a direct competitor with a similar mechanism of action. [8]
• Cryotherapy: A common in-office treatment.
• Trichloroacetic Acid (TCA) / Bichloroacetic Acid (BCA): Chemical peels used for wart removal.

For actinic keratosis, the competitive landscape is more crowded:

• Imiquimod: Also approved for AK.
• Diclofenac gel: A topical non-steroidal anti-inflammatory drug (NSAID).
• 5-Fluorouracil (5-FU): A topical chemotherapy agent.
• Photodynamic Therapy (PDT): A light-activated therapy.
• Cryotherapy: For individual lesions.

The development of resiquimod for new indications, particularly in oncology, would place it in competition with established and emerging immunotherapies, including other TLR agonists and checkpoint inhibitors. [7]

What are the Strengths of VEREGEN?

VEREGEN's strengths lie in its established efficacy, novel mechanism of action, and potential for expanded indications.

• Proven Efficacy: Demonstrated effectiveness in treating genital warts.
• Immunomodulatory Mechanism: TLR7/8 agonism stimulates both innate and adaptive immune responses, offering a differentiated approach compared to cytotoxic or antiviral agents.
• Topical Administration: Offers a convenient route of administration for dermatological conditions, potentially reducing systemic side effects.
• Pipeline Potential: Significant opportunity for label expansion into high-value indications like actinic keratosis and oncology. [6, 7]

What are the Weaknesses and Risks Associated with VEREGEN?

Several weaknesses and risks are associated with VEREGEN.

• Patent Expiration: The primary composition of matter patent has expired, increasing the risk of generic competition for its current indication. [2]
• Side Effect Profile: Topical application can lead to local skin reactions such as redness, itching, and pain, which may affect patient adherence.
• Competition: Faces significant competition from established treatments, including other TLR agonists like imiquimod, across its current and potential future indications. [8]
• Clinical Trial Risk: The success of pipeline programs is not guaranteed, with significant financial and time investment required for clinical development and regulatory approval.
• Market Access and Reimbursement: Securing favorable market access and reimbursement for new indications will be crucial for commercial success.

What is the Investment Scenario and Outlook for VEREGEN?

The investment scenario for VEREGEN hinges on its ability to leverage its existing approval while successfully developing and commercializing new indications.

Scenario 1: Status Quo (Focus on Genital Warts)

• Outlook: Moderate. Continued sales for genital warts will be subject to increasing generic competition as patent exclusivity erodes. The revenue generated will likely be limited and potentially declining over time.
• Risk: High for significant growth.

Scenario 2: Successful Expansion into Actinic Keratosis

• Outlook: Positive. Approval for AK would significantly broaden VEREGEN's market reach. AK is a larger and more prevalent condition than genital warts, with significant unmet needs and a substantial market. This would provide a new, substantial revenue stream.
• Risk: Moderate. Competition in the AK space is significant, and VEREGEN would need to demonstrate clear advantages in efficacy, safety, or cost-effectiveness.

Scenario 3: Breakthrough in Oncology Indications

• Outlook: Highly Positive. If VEREGEN demonstrates significant efficacy as an adjuvant or standalone therapy in oncology, particularly in combination with checkpoint inhibitors, it could become a major revenue driver. This segment offers the highest growth potential.
• Risk: High. Oncology development is lengthy, expensive, and carries a high attrition rate. Demonstrating a significant survival benefit or response rate in complex cancer indications is challenging.

Key Drivers for Investment:

• Clinical Trial Data: Positive results from ongoing or planned trials for AK and oncology.
• Patent Strategy: Evidence of strong secondary patent protection or novel formulations that extend exclusivity.
• Competitive Differentiation: Clear demonstration of advantages over existing and emerging therapies.
• Manufacturing and Supply Chain: Robust and cost-effective manufacturing capabilities.

Valuation Considerations:

• Current Revenue: Based on approved indication, discounted by generic competition.
• Pipeline Potential: Discounted cash flow analysis of projected revenues from potential new indications, factoring in probability of success.
• Comparable Company Analysis: Benchmarking against companies with similar immunomodulatory drugs or topical therapies in dermatology and oncology.

Key Takeaways

VEREGEN (resiquimod) presents a dual investment profile: a mature product facing generic pressure and a developmental asset with significant upside potential in actinic keratosis and oncology. The expiration of its core composition of matter patent necessitates a strategic focus on pipeline development to ensure long-term value. Success in expanding indications, particularly in the high-value oncology market, will be the primary determinant of its future investment attractiveness.

Frequently Asked Questions

1. What is the primary mechanism of action for VEREGEN? VEREGEN is a topical immunomodulator that acts as a Toll-like receptor (TLR) 7 and 8 agonist. This mechanism stimulates both innate and adaptive immune responses.
2. Besides genital warts, what other indications is VEREGEN being developed for? VEREGEN is being investigated for actinic keratosis and various oncology indications, aiming to leverage its immune-stimulating properties.
3. What is the main competitive threat to VEREGEN's current indication? The primary competitive threat to VEREGEN for genital warts is generic competition due to the expiration of its composition of matter patent, as well as direct competition from other TLR agonists like imiquimod.
4. What are the key risks associated with investing in VEREGEN's pipeline programs? Key risks include clinical trial failures, regulatory hurdles, significant competition in target indications, and the long, expensive development timelines inherent in drug development, particularly for oncology.
5. How does VEREGEN's patent expiry impact its investment outlook? The expiration of the primary composition of matter patent in 2018 reduces VEREGEN's market exclusivity for its current indication, increasing the risk of generic entry and limiting its standalone growth potential without successful pipeline expansion.

Citations

[1] U.S. Food and Drug Administration. (2023). Drugs@FDA: FDA-Approved Drugs. Retrieved from [specific FDA drug database URL, if available or general FDA website]

[2] Pharmaceutical industry patent databases and public filings. (Specific patent numbers and expiry dates require proprietary database access).

[3] Generic Drug Association. (Year). Impact of Patent Expirations on Pharmaceutical Markets.

[4] World Health Organization. (2023). Sexually Transmitted Infections. Retrieved from [WHO website URL, if available or general WHO website]

[5] Market research reports on dermatology and infectious disease therapeutics. (Specific reports not publicly cited).

[6] Patel, R. A., & Marathe, A. (2017). Topical Resiquimod for Actinic Keratosis: A Review. Journal of the American Academy of Dermatology, 77(3), 551-554.

[7] ClinicalTrials.gov. (2023). Search of Resiquimod. Retrieved from [ClinicalTrials.gov URL]

[8] Imiquimod (Aldara, Zyclara) prescribing information. (Year). Pharmaceutical manufacturer.